Use of the GnRH Antagonist Elagolix for Endometriosis in Relation to Hypoestrogenic Effect in Women
This literature review examined the GnRH antagonist elagolix as a medical therapy for endometriosis, finding it inhibits estrogen to suppress the growth of endometrial tissue.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This paper is a literature review discussing endometriosis and the GnRH antagonist elagolix, framing the treatment’s mechanism as suppression of estrogen to inhibit endometriosis tissue growth and thereby address outcomes such as dysmenorrhea, dyspareunia, and infertility. It synthesizes four focused studies and describes proposed etiologies of endometriosis (e.g., genetics, immunology, retrograde menstruation) at a high level rather than reporting original experimental results. The key conclusion is that elagolix is presented as a latest alternative medical therapy option for endometriosis, though the paper’s limitation is that it relies on secondary sources and does not provide new quantitative analysis. This paper is centrally about endometriosis — it focuses on elagolix’s hypoestrogenic effects in women with endometriosis.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
7,579 characters
· extracted from
oa-doi-fallback
· 2 sections
· click to expand
Abstract
Keywords
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (25)
- DIAGNOSIS DAN TATALAKSANA TERBARU ENDOMETRIOSIS via openalex
- Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study via openalex
- Elagolix in the treatment of endometriosis: impact beyond pain symptoms via openalex
- Elagolix Pada Endometriosis via openalex
- Endometriosis Dari Aspek teori sampai penanganan klinis via openalex
- FAKTOR RISIKO KEJADIAN ENDOMETRIOSIS via openalex
- Karakteristik Endometriosis di RSUP Dr. M. Djamil Padang Periode 2017 - 2019 via openalex
- PENATALAKSANAAN ENDOMETRIOSIS via openalex
- Perbedaan Derajat Nyeri Haid Pasien Endometriosis Sebelum dan Sesudah Tindakan Laparoskopi di RSUP Dr. Mohammad Hoesin Palembang via openalex
- Progestin Therapy in Endometriosis via openalex
- W3083532158 via openalex
- W2053475707 via openalex
- W3134269628 via openalex
- W6636232981 via openalex
- W6664012595 via openalex
- W6688057823 via openalex
- W6719239960 via openalex
- W6738521683 via openalex
- W6782700162 via openalex
- W6791182821 via openalex
- W2766446539 via openalex
- W6825072145 via openalex
- W2914681379 via openalex
- W2621312564 via openalex
- W2285321712 via openalex
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00